Drugs / AZD5672
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT00887770 | Apr → Jul 2009 | rheumatoid arthritis | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00871767 | Mar → May 2009 | rheumatoid arthritis | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00746837 | Aug 2008 → Jan 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00715702 | Jul 2008 → Feb 2009 | impaired renal function disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00723424 | Jul → Dec 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00722956 | Jul → Aug 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00711074 | Jun → Jul 2008 | rheumatoid arthritis | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00713544 | Jul 2008 → Apr 2009 | rheumatoid arthritis | AstraZeneca | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD5672 | “Single Oral Doses of AZD5672 (600 mg and 150 mg)” NCT00887770 ↗ |
| Action | Inhibit | “AZD5672 was a highly potent and selective antagonist of CCR5” PMID 20662070 ↗ Nov 2010 |
| Modality | Small molecule | “a small-molecule antagonist of CCR5” PMID 20662070 ↗ Nov 2010 |
| Route | Oral | “Treatment arms were AZD5672 (20, 50, 100, or 150 mg orally, once daily), matched placebo, or open-label etanercept (50 mg subcutaneously, once weekly).” PMID 20662070 ↗ Nov 2010 |
| Target | CCR5 | “blocking the chemokine receptor CCR5” PMID 20662070 ↗ Nov 2010 |